Added Treatment Plan Review process
Added videos to demonstrate selected Interventions
Corrections and bug fixes
Spend time with your client, not paperwork! Create
Treatment Plans in less time with more detail
than you would ever add without this clinical tool.
33 Treatment Planning modules allow you
to point and click to select Symptoms,
Diagnosis, Goals, Objectives, and Interventions.
Many Treatment Plan suggestions contain
Evidence-based Interventions informed by
research results proving their effectiveness.
The software works like you do when you
assess clients, select problems to focus
treatment on, and create a plan to implement.
Point and click to Create Prewritten Progress
Notes from our module content that is tightly
integrated with the Treatment Plan.
To see the feature list for version 16.1, click here. This update is FREE for anyone with TheraScribe 15.1 or newer AND an active Maintenance Plan. (Requires Windows 7 or newer.)
If you haven't renewed your maintenance plan and want to get the latest version of TheraScribe, please fill out a support ticket and we'll follow up with you.
PEC Technologies and Dr. Art Jongsma are committed to keeping TheraScribe as the most comprehensive Treatment Planning software for you with more frequent product updates. This release, version 16.1, contains several new features including videos demonstrating over 80 interventions, Treatment Plan review process and several bug fixes.
We highly value our customer base. We thank you for your loyalty and want you to know we are here to continue to provide the most versatile practice management experience available!
Read recommendations and testimonials, view a demonstration video and download a trial version of TheraScribe.
Try out the DSM-5 compliant version of TheraScribe!
We are confident you'll like what you see.
Login info: user = user; password = password
Help us as we continue to strive to make TheraScribe a product that works for you. Please complete this survey so that we can better understand the needs of your practice.